Carbiotix AB

Investor

Carbiotix AB

Description

biotechnology company focused on gut health solutions

Carbiotix AB

Address

Scheelevägen 22, Lund 22363
Lund, Sweden

Contact

info@carbiotix.com

Description

biotechnology company focused on gut health solutions

Matchmaking

Connect with Carbiotix AB

This entity is yours?

Update information

Position on the value chain

With the ultimate aim to create a European alliance for bioproduction in Europe, organisations have joined forces with COBIOE. Discover who are our associates.

Bio-resources and biobanking
  • Cells, tissues and humanized xeno-organs
  • Biosamples
  • Viral, phage or bacterial specimen
Identification of biotherapies
  • Target identification
  • Target validation
  • Screening
Drug design
  • Drug assessment
  • Drug engineering
  • In vitro preclinical studies
Clinical validation
  • Clinical trials
  • In vivo preclinical validation
  • Pre-industrial scale production
Production
  • Upstream processes
  • Downstream processes
  • Quality control
Market access
  • CE mark / market authorisation
  • Payment / Reimbursement
  • Care pathways

TRL

Carbiotix AB last news

08/07/2024

The Board of Directors of Carbiotix AB (publ) proposes a directed share issue of a maximum of approximately SEK 7.00 million

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, HONG KONG, NEW EALAND, SOUTH AFRICA, SOUTH KOREA, SWITERLAND, SINGAPORE, JAPAN, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD NOT BE IN COMPLIANCE WITH APPLICABLE LAWS OR REGULATIONS OR WOULD REQUIRE REGISTRATION OR SIMILAR MEASURES. The Board of Directors of Carbiotix AB (publ) ("Carbiotix" or the "Company") has today resolved to propose a directed share issue of a maximum of 175,000,024 shares at a

28/06/2024

Carbiotix AB's warrant exercise registered at the Swedish Companies Registration Office

Carbiotix AB ("Carbiotix" or "Company") today announces that the new shares from the exercise of warrants of series TO 3 have been registered with the Swedish Companies Registration Office. On 19 June 2024, the exercise period for warrants of series TO 3, which were issued in connection with Carbiotix's rights issue of units earlier in 2024, ended. As a result of the warrant exercise, 20,796,181 new shares have now been registered with the Swedish Companies Registration Office. The total number of shares in the Company after the exercise of warrants of series TO 3 amounts to 201,022,976 and

20/06/2024

Carbiotix AB announces the outcome of the exercise of warrants of series TO 3

On June 19, 2024, the exercise period for Carbiotix AB's ("Carbiotix" or "Company") warrants of series TO 3 ("TO 3") ended. In total, 20,796,181 warrants of series TO 3 have been exercised, corresponding to approximately 39 percent of the total number of warrants, which means that the Company receives approximately SEK 0.83 million before deductions for issue costs. During the period 5-19 June 2024, holders of warrants of series TO 3 have had the right to subscribe for shares with the support of warrants. One (1) warrant of series TO 3 gave the holder the right to subscribe for one (1) new